Despite significant impact biological treatment had on prospects of patients with IBD, there is still a substantial proportion of patients with either secondary loss of response or primary non-response to therapy. Strategies to avert treatment failure include dose optimization, selection of drugs with different mechanism of action or recently combination of two different targeted molecules in cases where inflammatory activity is not under control.